Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease

NCT03351738 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03351738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03351738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2017
Completion date
November 9, 2018
Enrollment
133 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

stable coronary heart disease